Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile Dysfunction

Type V-phosphodiesterase-inhibitors (PDE5i) are the first choice drugs in the treatment of erectile dysfunction (ED), being effective in 60–70% of patients. However, approximately 50% of patients per year discontinue the treatment with PDE5i after reporting poor drug efficacy or major adverse drug r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: Rocca, Maria Santa, Vignoli, Alessia, Tenori, Leonardo, Ghezzi, Marco, De Rocco Ponce, Maurizio, Vatsellas, Giannis, Thanos, Dimitris, Padrini, Roberto, Foresta, Carlo, De Toni, Luca
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7849189/
https://ncbi.nlm.nih.gov/pubmed/33536912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.602369
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars